Health Economics›Neuroblastoma›High Risk

High Risk

Neuroblastoma · 4 regimens

Cost estimates only — modelled on a typical patient (BSA 1.7 m², 70 kg, CrCl 90 mL/min) using the cheapest available formulary presentation. Excludes vial wastage, facility fees, supportive care, and infusion consumables. Not for billing, formulary decisions, or clinical use.

Filters

Y-axis

Cost vs Efficacy

No data points — cost or PFS missing for current selection.

Regimen	Biomarker	Cost/cycle ↓	Cycle	PFS ↕	OS ↕	Est. cycles	Course cost ↕	Evidence
COG A3973 with Myeloablative Therapy N/A - secondary systemic drug	—	R 141 679	28d	—	—	—	—	—
COG A3973 without Myeloablative Therapy N/A - secondary systemic drug	—	R 120 505	28d	—	—	—	—	—
COG ANBL0532 Regimen A N/A - secondary systemic drug	—	R 82 963	36d	—	—	—	—	—
COG ANBL 0032 Regimen A Variant #01	—	R 1 942	25d	—	—	—	—	—

4 of 4 regimens shown